title: Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy.
abstract: Adrenoleukodystrophy (ALD) is an X-linked disorder caused by a defect in the metabolism of long chain fatty acids leading to demyelination, neurodegeneration, and death. The disease typically presents in young boys and adolescent boys. Allogeneic bone marrow transplantation has been used to halt progression of the disease. However, many patients lack suitable HLA- matched related donors and must rely on unmatched donors for a source of stem cells. The purpose of this study was to evaluate outcomes of unrelated donor umbilical cord blood transplantation after chemotherapy-based myeloablative conditioning and retrospectively determine if baseline studies correlate and help predict outcome. Between November 22, 1996, and November 3, 2005, 12 boys with X-linked ALD who lacked HL- matched related donors were referred to Duke University Medical Center for transplantation. These children were conditioned with myeloablative therapy including busulfan, cyclophosphamide, and antithymocyte globulin before receiving umbilical cord-blood transplants from unrelated donors. Baseline studies of neurophysiologic, neuroimaging, and neurodevelopmental status were performed and patients were subsequently evaluated for survival, engraftment, graft-versus-host disease, and neurodevelopmental outcomes. A substudy evaluated whether baseline neuroimaging and neurophysiologic studies correlated with cognitive and motor function and if these studies were predictive of posttransplantation outcomes. The umbilical cord blood grafts had normal levels of very long chain fatty acids. They delivered a median of 6.98 x 10(7) nucleated cells per kilogram of recipient body weight and were discordant for up to 4 of 6 HLA markers. Neutrophil engraftment occurred at a median of 22.9 days after transplantation. Three patients had grade II-IV acute graft-versus-host disease; 2 had extensive chronic graft-versus-host disease. Cumulative incidence of overall survival of the group at 6 months is 66.7% (95% confidence interval 39.9-93.3%). Median follow-up was 3.3 years (range 12 days to 6.3 years). As previously reported with bone marrow transplantation, symptomatic patients faired poorly with lower survival and rapid deterioration of neurologic function. This study included 3 patients transplanted at a very young age (2.6-3.5 years) before the onset of clinical symptoms who continue to develop at a normal rate for 3-5 years posttransplant. Although baseline Loes scores correlated with cognitive and motor outcome, neurophysiologic studies failed to show statistically significant differences. Transplantation of boys with X-linked ALD using partial HLA-matched umbilical cord blood yields similar results to those previously reported after bone marrow transplantation. Superior outcomes were seen in neurologically asymptomatic boys less than 3.5 years of age at the time of transplantation. Baseline Loes scores were a strong predictor of cognitive and motor outcome.
authors.affiliation: Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, NC, USA.
authors.forename: Donald
authors.initials: D
authors.lastname: Beam
authors.forename: Michele D
authors.initials: MD
authors.lastname: Poe
authors.forename: James M
authors.initials: JM
authors.lastname: Provenzale
authors.forename: Paul
authors.initials: P
authors.lastname: Szabolcs
authors.forename: Paul L
authors.initials: PL
authors.lastname: Martin
authors.forename: Vinod
authors.initials: V
authors.lastname: Prasad
authors.forename: Suhag
authors.initials: S
authors.lastname: Parikh
authors.forename: Tim
authors.initials: T
authors.lastname: Driscoll
authors.forename: Srini
authors.initials: S
authors.lastname: Mukundan
authors.forename: Joanne
authors.initials: J
authors.lastname: Kurtzberg
authors.forename: Maria L
authors.initials: ML
authors.lastname: Escolar
mesh_terms: D000326:Adrenoleukodystrophy / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003071:Cognition; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D006085:Graft Survival; D006086:Graft vs Host Disease; D006650:Histocompatibility Testing; D006801:Humans; D007804:Language Development; D008297:Male; D009043:Motor Activity; D019653:Myeloablative Agonists / Q000627:therapeutic use; D009482:Neurophysiology; D011237:Predictive Value of Tests; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome
chemical_list: D019653:Myeloablative Agonists